Understanding how EP300 mutations affect bladder cancer and treatment response
Official title: The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response
Funded at Sloan-Kettering Inst Can Research · NIH-11027422 · Data updated 2026-11-12
This study is looking at how changes in the EP300 gene might make bladder cancer harder to treat with current medications, and it aims to find new ways to help patients respond better to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $583,973 |
| NIH project number | 1R01CA296335-01 |
| Project ID | NIH-11027422 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic bladder or upper tract urothelial cancer who have mutations in the EP300 gene.
✕Less likely to help
Patients with non-metastatic bladder cancer or those without EP300 mutations may not benefit from this research.
What this research studies
This research investigates the role of EP300 gene mutations in bladder cancer, particularly how these mutations may contribute to resistance against current treatments like erdafitinib. The study aims to explore the biological effects of these mutations and their impact on the effectiveness of therapies targeting the IL-6-JAK1-STAT3 signaling pathway. By analyzing a large cohort of patients with urothelial cancer, the research seeks to identify potential strategies to overcome treatment resistance and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with bladder cancer, particularly those who have developed resistance to existing therapies.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Solit, David B. — Sloan-Kettering Inst Can Research
- Study coordinator: Solit, David B.
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.